纳斯达克： -- -- --

最近浏览

实时行情

意见反馈

科兴生物

NASDAQ:SVA 延时15分钟
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 振幅：
    每股收益：
成交量

董事会

Andrew Y. Yan
Andrew Y. Yan founded SAIF Partners III LP in 2001, where he is working as Managing Partner from 2001. Mr. Yan also currently works at Asset Management Association of China, as Vice Chairman, Sinovac Biotech Ltd., as Chairman from 2025, PetroChina Co., Ltd., as Independent Non-Executive Director from 2024, and various other companies. Mr. Yan also formerly worked at NVC International Holdings Ltd., as Chairman from 2012 to 2013, Intelligroup, Inc., as Director, China Southern Airlines Co. Ltd., as Independent Non-Executive Director from 2021 to 2022, and various other companies. Mr. Yan received his graduate degree in 1986 from Peking University, graduate degree in 1989 from Princeton University, and undergraduate degree in 1982 from Nanjing University of Aeronautics & Astronautics.
Yuk Lam Lo
Yuk Lam Lo is the founder of Hk Bio-Med Innotech Association. Current jobs include Vice Chairman at Santai Eco Fishery Ltd., Chairman at Lo s Associates Ltd., Vice Chairman at APlus OTC Health Group Ltd., Chairman at Lo & Associates, Chairman at GT Capital Investment Ltd. since 2018, Independent Director at Sinovac Biotech Ltd. since 2006, Independent Non-Executive Director at Luye Pharma Group Ltd. since 2014, Director at Chinese Manufacturers' Association of Hong Kong, Senior Director at Questmark Asia Ltd., Director at Applied Research Council, Independent Non-Executive Director at Zhaoke Ophthalmology Ltd. since 2021, Independent Non-Executive Director at HaploX Investment Holding Ltd., Member at The Hong Kong University of Science & Technology, Member at Hong Kong Baptist University, Executive Vice President at Asian College of Knowledge Management, Partner at Hongsen Investment Management Ltd. since 2019, and President at Santai Biotechnology Research Institute Co. Ltd. Former jobs include Independent Non-Executive Director at CSPC Pharmaceutical Group Ltd. from 2014 to 2021, Non-Executive Director at DIT Group Ltd. from 2002 to 2011, Independent Director at Shangpharma Corp. from 2010 to 2013, Director at Industry & Technology Development Council, and Member at Research Grants Council from 2007 to 2009. Education includes an undergraduate degree from The University of Waterloo.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Jian Li
Jian Li is currently an Independent Director at Sinovac Biotech Ltd., a Non-Executive Director at China Hanking Holdings Ltd., a Non-Executive Director at COFCO Womai Co., Ltd., and a Partner at SAIF Partners Ltd. (China). Previously, he served as a Director at Bona Film Group Co., Ltd., a Director at Yayi International, Inc., a Non-Executive Director at Greenway Mining Group Ltd., a Principal at Rimasia Capital Partners LP, and the Chief Financial Officer at TopSec Holdings Ltd. Mr. Li obtained his undergraduate degree from Amherst College in 1990.
Meng Mei
Meng Mei is the founder of Tus-Holdings Co., Ltd., which was founded in 1994. He served as the Chairman of Tus-Holdings Co., Ltd. from 1994 to 2016. Currently, Mr. Mei holds the position of Independent Director at Sinovac Biotech Ltd. since 2012 and Director at Beijing PARATERA Tech Corp., Ltd. since 2019. In the past, he held the position of Chairman at Tus Science & Technology Service Co., Ltd. and Director at Beijing Sumavision Technologies Co., Ltd. Mr. Mei completed his undergraduate degree at Tsinghua University.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Simon J. Anderson
Simon J. Anderson is currently Director at O903658 B.C. Ltd since 2009, Director at Tsar Emerald Corp., Independent Director at IBC Advanced Alloys Corp. since 2016, Chief Financial Officer & Director at Anibesa Energy Metals Corp. since 2018, Director at Sinovac Biotech Ltd. starting 2025, Chief Financial Officer at Gold Strike Resources Corp. since 2012, Chief Financial Officer & Secretary at Swift Power Corp. since 2010, President at S2 Management, Inc. since 2008, and Member of The Chartered Professional Accountants of British Columbia. Former roles include Director at WEX Pharmaceuticals, Inc., President & Director at Kirkland Lake Discoveries Corp. in 2012, Independent Director at Sinovac Biotech Ltd. from 2004 to 2025, Secretary at Ikona Gear International, Inc. in 2005, Chief Financial Officer at SHEP Technologies, Inc., Doublestar Resources Ltd., Cerro Mining Corp., Arco Resources Corp., Simba Gold Corp. from 2011 to 2012, Minco Capital Corp. from 2005 to 2006, Patriot Resources Corp., and Bluerock Resources Ltd. from 2007 to 2009. Also served as Chief Financial Officer & Secretary at Buffalo Gold Ltd. from 1996 to 2009, Chief Financial Officer at Argentum Silver Corp. from 2011 to 2014, Vice President at MCSI Consulting Services, Inc. from 1996 to 2008, Chief Financial Officer at Prime Mining Corp. from 2007 to 2020, Principal at BDO Dunwoody LLP and Collins Barrow Calgary LLP, and Member of The Institute of Chartered Accountants of British Columbia. Education includes undergraduate studies at the University of British Columbia.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Shan Fu
Shan Fu currently works at BioDlink International Co., Ltd., as Executive Chairman from 2025, VISEN Pharmaceuticals, as Chairman from 2025, dMed Biopharmaceutical Technology (Shanghai) Co., Ltd., as Director from 2019, New Frontier Health Corp., as Director from 2019, VISEN Pharmaceuticals (Shanghai) Co., Ltd., as Non-Executive Director from 2021, Lepu Scientech Medical Technology (Shanghai) Co., Ltd., as Non-Executive Director from 2021, Esco Lifesciences Group Ltd., as Non-Executive Director from 2021, Sinovac Biotech Ltd., as Director from 2025, and Vivo Capital LLC, as Managing Partner from 2013. Mr. Fu also formerly worked at Sinovac Biotech Ltd., as Independent Non-Executive Director from 2018 to 2025, China Animal Healthcare Ltd., as Non-Executive Director, National Development & Reform Commission, as Director-General Office from 2003 to 2008, State Economic & Trade Commission, as Director-Policy & Foreign Capital Division, The Blackstone Group, as Senior Managing Director from 2008 to 2013, Blackstone (Shanghai) Equity Invt Mgmt Co. Ltd., as Senior Managing Director from 2008 to 2013, InnoCare Pharma Ltd., as Non-Executive Director from 2019 to 2023, and Genetron Holdings Ltd., as Director. Mr. Fu received his undergraduate degree in 1988 from Peking University and graduate degree in 1991 from Peking University.
Sven Heinz Borho
Mr. Sven H. Borho, CFA, is an Independent Non-Executive Director at Sinovac Biotech Ltd., a Managing Partner at OrbiMed Advisors LLC, a Managing Partner at OrbiMed Advisors Private Equity and a Portfolio Manager at OrbiMed Capital LLC. He is on the Board of Directors at Sinovac Biotech Ltd. and Worldwide Healthcare Trust Plc. Mr. Borho was previously employed as a Chief Executive Officer by K Bygg stergyllen AB. He also served on the board at The Biotech Growth Trust Plc. He studied business administration at Bayreuth University in Germany and received a M.Sc. (Econs.), Accounting and Finance, from The London School of Economics.
Simon J. Anderson
Simon J. Anderson is currently Director at O903658 B.C. Ltd since 2009, Director at Tsar Emerald Corp., Independent Director at IBC Advanced Alloys Corp. since 2016, Chief Financial Officer & Director at Anibesa Energy Metals Corp. since 2018, Director at Sinovac Biotech Ltd. starting 2025, Chief Financial Officer at Gold Strike Resources Corp. since 2012, Chief Financial Officer & Secretary at Swift Power Corp. since 2010, President at S2 Management, Inc. since 2008, and Member of The Chartered Professional Accountants of British Columbia. Former roles include Director at WEX Pharmaceuticals, Inc., President & Director at Kirkland Lake Discoveries Corp. in 2012, Independent Director at Sinovac Biotech Ltd. from 2004 to 2025, Secretary at Ikona Gear International, Inc. in 2005, Chief Financial Officer at SHEP Technologies, Inc., Doublestar Resources Ltd., Cerro Mining Corp., Arco Resources Corp., Simba Gold Corp. from 2011 to 2012, Minco Capital Corp. from 2005 to 2006, Patriot Resources Corp., and Bluerock Resources Ltd. from 2007 to 2009. Also served as Chief Financial Officer & Secretary at Buffalo Gold Ltd. from 1996 to 2009, Chief Financial Officer at Argentum Silver Corp. from 2011 to 2014, Vice President at MCSI Consulting Services, Inc. from 1996 to 2008, Chief Financial Officer at Prime Mining Corp. from 2007 to 2020, Principal at BDO Dunwoody LLP and Collins Barrow Calgary LLP, and Member of The Institute of Chartered Accountants of British Columbia. Education includes undergraduate studies at the University of British Columbia.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Shan Fu
Shan Fu currently works at BioDlink International Co., Ltd., as Executive Chairman from 2025, VISEN Pharmaceuticals, as Chairman from 2025, dMed Biopharmaceutical Technology (Shanghai) Co., Ltd., as Director from 2019, New Frontier Health Corp., as Director from 2019, VISEN Pharmaceuticals (Shanghai) Co., Ltd., as Non-Executive Director from 2021, Lepu Scientech Medical Technology (Shanghai) Co., Ltd., as Non-Executive Director from 2021, Esco Lifesciences Group Ltd., as Non-Executive Director from 2021, Sinovac Biotech Ltd., as Director from 2025, and Vivo Capital LLC, as Managing Partner from 2013. Mr. Fu also formerly worked at Sinovac Biotech Ltd., as Independent Non-Executive Director from 2018 to 2025, China Animal Healthcare Ltd., as Non-Executive Director, National Development & Reform Commission, as Director-General Office from 2003 to 2008, State Economic & Trade Commission, as Director-Policy & Foreign Capital Division, The Blackstone Group, as Senior Managing Director from 2008 to 2013, Blackstone (Shanghai) Equity Invt Mgmt Co. Ltd., as Senior Managing Director from 2008 to 2013, InnoCare Pharma Ltd., as Non-Executive Director from 2019 to 2023, and Genetron Holdings Ltd., as Director. Mr. Fu received his undergraduate degree in 1988 from Peking University and graduate degree in 1991 from Peking University.
Shuge Jiao
Shuge Jiao has held a position as Director at Sinovac Biotech Ltd. since 2025.
Wei Dong Yin
Wei Dong Yin currently works at Sinovac Biotech Ltd., as Chief Executive Officer & Executive Director from 2025, Tangshan Yian Biological Engineering Co., Ltd., as Chairman from 2013, Sinovac Biotech (Hong Kong) Ltd., as Chairman, Sinovac (Dalian) Vaccine Technology Co. Ltd., as Chairman, and Zhongguancun Listed Cos. Association, as President. Dr. Yin also formerly worked at Sinovac Biotech Co. Ltd., as Chairman & Chief Executive Officer from 2013 to 2018 and Sinovac Biotech Ltd., as Chairman, President, CEO, Secretary & MD from 2003 to 2025. Dr. Yin received his Masters Business Admin degree from National University of Singapore.
Yu Min Qiu
Mr. Yu Min Qiu, CFA MBA, is a Partner at Advantech Capital /CN/, a Member at Institute of Management Accountants, Inc. and a Member at CFA Institute. He is on the Board of Directors at Sinovac Biotech Ltd., Biopharm International Co. Ltd., Heal Force Bio-meditech Holdings Ltd., Kbp Biosciences Holdings Ltd., KBP Biosciences USA, Inc., Shandong Dongyao Pharmaceutical Co. Ltd., Shanghai Wiwide Ukang Network Technology Co. Ltd., Shenzhen Huakang Quanjing Information Technology Co., Ltd., Zhejiang Daoming Pharmaceutical Technology Co. Ltd. and Harbour BioMed (Shanghai) Co., Ltd. Mr. Qiu was previously employed as a Non-Executive Director by Alphamab Oncology, a Non-Executive Director by TOT BIOPHARM International Co. Ltd., a Non-Executive Director by HBM Holdings Ltd., an Executive Director by New Horizon Capital (Group) Ltd., a Vice President by GL Capital Group, a Manager-Healthcare Advisory Team by PricewaterhouseCoopers Consultants (Shenzhen) Ltd., and an Executive Director by Deloitte China. He also served on the board at Tot Biopharm Co. Ltd. He received his undergraduate degree from East China University of Science & Technology and an MBA from the University of British Columbia.
Yu Wang
Dr. Yu Wang is on the Board of Directors at Sinovac Biotech Ltd. and The Chinese Medical Association. Dr. Wang was previously employed as a Non-Executive Director by Aceso Life Science Group Ltd. He received his doctorate degree from Beijing Medical University.